[go: up one dir, main page]

CO2018004473A2 - Compuestos agonistas de ppar y composiciones farmaceuticas - Google Patents

Compuestos agonistas de ppar y composiciones farmaceuticas

Info

Publication number
CO2018004473A2
CO2018004473A2 CONC2018/0004473A CO2018004473A CO2018004473A2 CO 2018004473 A2 CO2018004473 A2 CO 2018004473A2 CO 2018004473 A CO2018004473 A CO 2018004473A CO 2018004473 A2 CO2018004473 A2 CO 2018004473A2
Authority
CO
Colombia
Prior art keywords
ppar
diseases
pharmaceutical compositions
agonist compounds
compounds
Prior art date
Application number
CONC2018/0004473A
Other languages
English (en)
Inventor
Michael Downes
M Ronald Evans
Arthur Kluge
Bharat Lagu
Masanori Miura
Sunil Kumar Panigrahi
Michael Patane
Susanta Samajdar
Ramesh Senaiar
Taisuke Takahashi
Original Assignee
Mitobridge Inc
Salk Inst Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018004473(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitobridge Inc, Salk Inst Biological Studies filed Critical Mitobridge Inc
Publication of CO2018004473A2 publication Critical patent/CO2018004473A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos derivados de imidazol y sales farmacéuticas de los mismos y composiciones que comprenden dichos compuestos que son útiles para incrementar la actividad de PPARδ. Los compuestos y composiciones que se proporcionan son útiles para el tratamiento de enfermedades relacionadas con PPARδ tales como enfermedades musculares, enfermedades vasculares, enfermedades desmilienizantes y enfermedades metabólicas.
CONC2018/0004473A 2015-10-07 2016-10-05 Compuestos agonistas de ppar y composiciones farmaceuticas CO2018004473A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
US201562243263P 2015-10-19 2015-10-19
US201662352348P 2016-06-20 2016-06-20
PCT/US2016/055521 WO2017062468A1 (en) 2015-10-07 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2018004473A2 true CO2018004473A2 (es) 2018-09-20

Family

ID=57200096

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004473A CO2018004473A2 (es) 2015-10-07 2016-10-05 Compuestos agonistas de ppar y composiciones farmaceuticas

Country Status (28)

Country Link
US (6) US10399958B2 (es)
EP (3) EP3770146B1 (es)
JP (2) JP6657413B2 (es)
KR (2) KR102667386B1 (es)
CN (3) CN113004205B (es)
AU (3) AU2016333963C1 (es)
BR (1) BR112018006866B1 (es)
CA (1) CA3000431A1 (es)
CO (1) CO2018004473A2 (es)
DK (1) DK3359528T3 (es)
EA (1) EA037371B1 (es)
ES (3) ES2906379T3 (es)
HK (1) HK1257907A1 (es)
HU (1) HUE058154T2 (es)
IL (3) IL258225B (es)
JO (3) JO3738B1 (es)
MA (2) MA52648A (es)
MX (3) MX380281B (es)
MY (1) MY203081A (es)
NZ (1) NZ740846A (es)
PH (1) PH12018500762A1 (es)
PL (1) PL3359528T3 (es)
PT (1) PT3359528T (es)
SG (1) SG10201906400SA (es)
TW (3) TWI730408B (es)
UA (1) UA122237C2 (es)
WO (1) WO2017062468A1 (es)
ZA (4) ZA201802029B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912681B2 (en) 2016-10-05 2024-02-27 Mitobridge, Inc. Crystalline and salt forms of PPAR agonist compounds

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102667386B1 (ko) 2015-10-07 2024-05-21 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
RU2746602C2 (ru) 2016-04-13 2021-04-16 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
TWI778982B (zh) * 2016-10-05 2022-10-01 美商米突倍基公司 治療急性腎損傷之方法
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
IL308711A (en) 2021-06-02 2024-01-01 Astellas Pharma Inc Methods of using PPAR agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
HUP0201020A3 (en) 1999-02-26 2003-04-28 Bristol Myers Squibb Co Novel sulfonamide compounds and uses thereof
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
NZ522823A (en) 2000-08-17 2004-11-26 Pfizer Substituted imidazoles as TAFIa inhibitors
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
AU2004275637C1 (en) 2003-09-26 2010-11-25 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
CN101031541A (zh) 2004-09-06 2007-09-05 弗·哈夫曼-拉罗切有限公司 4－氨基甲基苄脒衍生物及其作为因子Ⅷa抑制剂的用途
CA2597148A1 (en) 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Amide derivatives as ppar activators
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
US7723369B2 (en) 2006-01-30 2010-05-25 Transtech Pharma, Inc. Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors
KR20080098548A (ko) 2006-03-28 2008-11-10 노파르티스 아게 Ｇ 단백질 관련 질환의 치료를 위한 아미드 유도체 및 그의투여
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CN101085772A (zh) * 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
JP2010520873A (ja) 2007-03-07 2010-06-17 ドン・ア・ファーム・カンパニー・リミテッド ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体、その方法およびそれを含む医薬組成物
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
CA2710764A1 (en) 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
WO2014033088A1 (en) 2012-08-28 2014-03-06 Koc Universitesi Bone plate
AU2014247953A1 (en) 2013-04-05 2015-11-12 Mitobridge, Inc. PPAR agonists
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
US20170305894A1 (en) 2014-10-08 2017-10-26 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
KR102667386B1 (ko) 2015-10-07 2024-05-21 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
RU2746602C2 (ru) 2016-04-13 2021-04-16 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
TWI778982B (zh) 2016-10-05 2022-10-01 美商米突倍基公司 治療急性腎損傷之方法
SI3523283T1 (sl) * 2016-10-05 2021-11-30 Mitobridge, Inc. Kristalinične oblike in oblike soli spojin agonista PPAR
UA124777C2 (uk) * 2016-12-30 2021-11-17 Мітобрідж, Інк. Інгібітори полі(адф-рибоза)полімерази (parp)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912681B2 (en) 2016-10-05 2024-02-27 Mitobridge, Inc. Crystalline and salt forms of PPAR agonist compounds

Also Published As

Publication number Publication date
US20200157074A1 (en) 2020-05-21
EP3770146C0 (en) 2024-07-24
EA201890776A1 (ru) 2018-09-28
JOP20200231A1 (ar) 2022-10-30
TW201943705A (zh) 2019-11-16
TWI730006B (zh) 2021-06-11
TW201722919A (zh) 2017-07-01
US10906885B2 (en) 2021-02-02
CN113024467B (zh) 2024-08-06
PL3359528T3 (pl) 2022-05-30
EP3795566A1 (en) 2021-03-24
KR20210126150A (ko) 2021-10-19
US20230373948A1 (en) 2023-11-23
US20190084958A1 (en) 2019-03-21
MA52098A (fr) 2021-01-27
ZA201802029B (en) 2022-01-26
MX2018004295A (es) 2018-08-09
MX392523B (es) 2025-03-24
IL275387A (en) 2020-07-30
UA122237C2 (uk) 2020-10-12
EP3770146B1 (en) 2024-07-24
SG10201906400SA (en) 2019-08-27
BR112018006866A2 (pt) 2018-10-16
WO2017062468A1 (en) 2017-04-13
BR112018006866B1 (pt) 2023-11-21
JP2018534355A (ja) 2018-11-22
ES2988059T3 (es) 2024-11-19
JP6866514B2 (ja) 2021-04-28
IL275392B (en) 2022-05-01
ZA202003663B (en) 2022-08-31
EP3770146A1 (en) 2021-01-27
MA52648A (fr) 2021-10-13
US11578052B2 (en) 2023-02-14
AU2016333963C1 (en) 2021-05-27
CN113024467A (zh) 2021-06-25
JP2020075939A (ja) 2020-05-21
ZA202003662B (en) 2022-08-31
CN113004205A (zh) 2021-06-22
MX2020011100A (es) 2022-05-23
US20240417383A1 (en) 2024-12-19
TW202012375A (zh) 2020-04-01
AU2016333963A1 (en) 2018-04-12
ES2949852T3 (es) 2023-10-03
AU2019283837B2 (en) 2020-12-24
KR102667386B1 (ko) 2024-05-21
MX2020011099A (es) 2022-05-23
CN108349904A (zh) 2018-07-31
KR20180095797A (ko) 2018-08-28
AU2016333963B2 (en) 2021-01-07
TWI742479B (zh) 2021-10-11
US20190337920A1 (en) 2019-11-07
ZA202003664B (en) 2022-08-31
AU2020281069A1 (en) 2021-01-07
PT3359528T (pt) 2022-04-07
WO2017062468A8 (en) 2017-05-11
AU2020281069B2 (en) 2022-10-27
JOP20200230A1 (ar) 2022-10-30
JO3738B1 (ar) 2021-01-31
MX392524B (es) 2025-03-24
JP6657413B2 (ja) 2020-03-04
ES2906379T3 (es) 2022-04-18
EP3359528A1 (en) 2018-08-15
NZ740846A (en) 2024-12-20
DK3359528T3 (en) 2022-03-07
IL258225A (en) 2018-05-31
MX380281B (es) 2025-03-12
MY203081A (en) 2024-06-07
IL275387B (en) 2021-08-31
IL275392A (en) 2020-07-30
US10399958B2 (en) 2019-09-03
HK1257907A1 (zh) 2019-11-01
PH12018500762A1 (en) 2018-10-29
CN113004205B (zh) 2024-07-02
US20210253549A1 (en) 2021-08-19
EP3795566B1 (en) 2023-04-19
HUE058154T2 (hu) 2022-07-28
EP3359528B1 (en) 2022-01-12
AU2019283837A1 (en) 2020-01-16
CA3000431A1 (en) 2017-04-13
IL258225B (en) 2021-08-31
US10479775B1 (en) 2019-11-19
EA037371B1 (ru) 2021-03-19
KR102667385B1 (ko) 2024-05-21
TWI730408B (zh) 2021-06-11
CN108349904B (zh) 2021-08-31

Similar Documents

Publication Publication Date Title
CO2018004473A2 (es) Compuestos agonistas de ppar y composiciones farmaceuticas
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018004124A2 (es) Compuestos heterocíclicos
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
EA201890052A1 (ru) Регуляторы nrf2
CL2014002541A1 (es) Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.
MX2017014375A (es) Moduladores del ccr2.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2018005639A2 (es) Sililfenoxiheterociclos trisustituidos y análogos
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
MX373549B (es) Derivado de pirazol amida.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
ECSP14030779A (es) Inhibidores del nampt
MX2017001553A (es) Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo